Skip to main content
SLU publication database (SLUpub)

Research article2007Peer reviewed

Immunogenicity and protective effect against murine cerebral neosporosis of recombinant NcSRS2 in different iscom formulations

Pinitkiatisakul S, Friedman M, Wikman M, Mattsson JG, Lovgren-Bengtsson K, Stahl S, Lunden A

Abstract

Recombinant NcSRS2, a major immunodominant surface antigen of the intracellular protozoan parasite Neospora caninum, was used as a model antigen to compare the immunogenicity of iscoms prepared according to three different methods. Two NcSRS2 fusion proteins were used, one that was biotinylated upon expression in Escherichia coli and linked to Ni2+-loaded iscom matrix (iscom without any protein) via a hexabistidyl (HiS(6)-tagged streptavidin fusion protein, and another that contained both a HiS(6)-tag and streptavidin (HiS(6)-SA-SRS2') and was coupled to either Ni2+-loaded or biotinylated matrix. While all three iscom preparations induced N. caninum specific antibodies at similar levels, HiS(6)-SA-SRS2' coupled to biotinylated matrix generated the strongest cellular responses measured as in vitro proliferation and production of interferon-gamma and interleukin-4 after antigen stimulation of spleen cells. However, the relationship between the levels of these cytokines as well as between IgG1 and IgG2a titres in serum induced by the three iscom preparations were similar, indicating that the balance between Th1 and Th2 responses did not differ. After challenge infection, mice immunised with His(6)-SA-SRS2' coupled to biotinylated matrix had significantly lower amounts of parasite DNA in their brains compared to the other immunised groups. Possible reasons for the performance of the different iscom formulations are discussed. (C) 2007 Elsevier Ltd. All rights reserved

Published in

Vaccine
2007, Volume: 25, number: 18, pages: 3658-3668
Publisher: ELSEVIER SCI LTD

      SLU Authors

        • UKÄ Subject classification

        Veterinary Science
        Animal and Dairy Science

        Publication identifier

        DOI: https://doi.org/10.1016/j.vaccine.2007.01.074

        Permanent link to this page (URI)

        https://res.slu.se/id/publ/15103